←
Poolbeg Pharma1,235 posts
Poolbeg Pharma avatar

Poolbeg Pharma

@PoolbegPharma

Clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field & developing an oral obesity therapy Ticker: POLB

◷ Joined April 2021▧ 951 Photos and videos
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Sep 24

Poolbeg Pharma's TOPICAL trial will continue as planned following a positive interim safety review of POLB 001. ✅ No protocol changes required ✅ Recruitment ongoing across UK clinical sites ✅ Further enrolment, site activations and partnering discussions ahead Read the full announcement & register for today's investor presentation: londonstockexchange.com/news… #POLB #Biotech #AIM

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 17

Congratulations to Professor Luke O’Neill, Non-Executive Director & Scientific Advisory Board member of Poolbeg Pharma, on his appointment as Vice-President for Life Sciences at the European Research Council (ERC). A fantastic recognition of Luke’s contribution to life sciences and his continued leadership within the European scientific community. We are incredibly proud to have Luke as a member of the Poolbeg Pharma Board and wish him every success in this important new role.

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 13

A valuable week at #BIOEurope 2026 🌍 A highlight was CEO Jeremy Skillington joining a workshop on communicating complex science clearly to investors and pharma partners. Highly relevant as Poolbeg Pharma advances POLB 001 and its partnering-led strategy. #POLB

Post attachmentPost attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 12

We’re looking forward to attending London Life Sciences Week 2026, connecting with biotech, pharmaceutical and life sciences leaders from across the industry. Attending from Poolbeg will be: 🔵 Jeremy Skillington, CEO 🔵 Ian O'Connell, CFO 🔵 Cathal Friel, Executive Chair Going to be there too? We’d be delighted to connect. Email IR@poolbegpharma.com to arrange a meeting with the team. #LondonLifeSciencesWeek #Biotech #LifeSciences

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 10

CEO Jeremy Skillington, shares a quick overview of his workshop discussion, “Pitch, Present, Persuade: Become a Powerful #Corporate Communicator”, hosted by @OptimumComms on the opening day of #BIOEurope. At Poolbeg, this is particularly relevant as we progress the #POLB 001 TOPICAL trial and continue #partnering discussions.

0:39
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 9

This #IrishScienceWeek, we celebrate the scientists and innovators advancing healthcare worldwide. 🔬 At Poolbeg Pharma, we're proud to be part of Ireland's thriving life sciences ecosystem, driving innovation to address unmet medical needs and improve patient outcomes. #ScienceWeek #Biotech

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 6

🎤 #BIOEurope 2026! We’re looking forward to seeing our CEO, Jeremy Skillington, PhD, take part in the “Pitch, Present, Persuade: Become a Powerful Corporate Communicator” workshop at BIO-Europe on Monday, 9 November. 📍 Ecosystem Innovation Stage 📅 Monday, 9 November ⏰ 09:00–10:00 The session will bring together CEO, investor and BD perspectives to explore how biotech companies can communicate their science, strategy and commercial opportunity in a clear and compelling way. Learn more: informaconnect.com/bioeurope… #BIOEurope #Biotech #LifeSciences #BusinessDevelopment #PoolbegPharma

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 5

New to Poolbeg Pharma? 🎥 Our CEO Jeremy Skillington shares a quick overview of our lead asset POLB 001, its commercial opportunity and our partnering-led strategy. 🔹 POLB 001 – oral therapy to prevent Cytokine Release Syndrome associated with cancer immunotherapies 🔹 TOPICAL trial progressing, with recruitment ongoing and a positive review from the interim safety cohort 🔹 >$10bn market opportunity across multiple myeloma and diffuse large B-cell lymphoma 🔹 Strong partnering package supported by global IP, FDA Orphan Drug Designation, positive FDA pre-IND feedback and ongoing clinical development 🔹Active and ongoing partnering discussions with open data room 🔹 Funded into Q2 2028, providing a strong foundation as we advance our clinical and partnering objectives Learn more about Poolbeg Pharma here:poolbegpharma.com/investors/ #POLB #Investors #PoolbegPharma

1:30
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Nov 2

A partner-ready biotech asset needs more than strong science. At @_investorsummit , Chris Grimes-Crompton highlights the full equation for #POLB: 🔹Robust clinical evidence 🔹Clear value for payers 🔹A reimbursement case that protects asset value

1:16
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Oct 29

Last night, our CEO Jeremy Skillington presented at the @ShardSB Investor Evening in London, sharing the Poolbeg Pharma story with attendees before an evening of networking. A big thank you to Shard Capital for organising and to everyone who joined us, participated in the Q&A and spoke with the team afterwards. 📸 Check out some photos from the evening below. You can also view the presentation deck used at the event on our website: poolbegpharma.com/investors/…

Post attachmentPost attachmentPost attachmentPost attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Oct 28

🎙️ More Bitesize Biotech is coming soon… Have you tuned in to Episode 1? bitesizebiotech.carrd.co/ In the first episode of Poolbeg Pharma’s #podcast series, Principal Scientist Liam Tremble is joined by Patient Advocate Bob Munro to discuss: 🔬 The role of the patient voice in #drugdevelopment 🧬 The real-world impact of medical innovation 🏥 The need to address #CRS #PoolbegPharma #BitesizeBiotech #Biotech #Healthcare

Post attachment
Poolbeg Pharma avatar
Poolbeg Pharma@PoolbegPharma·Oct 27

14 years after a myeloma diagnosis. 9–10 drugs over 11 years. Then a clinical trial led to Bob Munro’s first complete remission. On #POLB’s Bitesize Biotech, Bob shares how new immunotherapies changed the course of his disease and opened up options when others had run out. Tune into our podcast episode here: bitesizebiotech.carrd.co/

1:22